DelveInsight reports that the Opioid Withdrawal Syndrome pipeline includes over 4 key companies actively developing more than 4 therapeutic candidates.
Opioid Withdrawal Syndrome Overview:
Opioid Withdrawal Syndrome is a potentially serious condition that arises from dependence on opioids, a class of drugs often prescribed for severe pain. The syndrome occurs when opioid use is abruptly reduced or discontinued after prolonged and heavy use, triggering a variety of withdrawal symptoms. Common symptoms include anxiety, chills or goosebumps, restlessness, insomnia, frequent yawning, runny nose, watery eyes, fever, nausea, vomiting, and diarrhea, among others.
The locus coeruleus, located at the base of the brain, plays a central role in triggering these withdrawal symptoms. Current treatment approaches for Opioid Withdrawal Syndrome include gradual tapering of full opioid agonists such as methadone, short-term use of partial mu-opioid agonists like buprenorphine, and detoxification protocols using opioid antagonists such as naltrexone and naloxone.
Download our report @ https://www.delveinsight.com/report-store/obstructive-sleep-apnea-osa-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
"Opioid Withdrawal Syndrome Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Opioid Withdrawal Syndrome Therapeutics Market.
Key Takeaways from the Opioid Withdrawal Syndrome Pipeline Report
-
DelveInsight’s report on the Opioid Withdrawal Syndrome (OWS) pipeline highlights a focused space, with over 4 companies actively developing more than 4 therapeutic candidates.
-
In May 2018, the FDA approved Lucemyra (lofexidine hydrochloride), the first non-opioid medication aimed at easing withdrawal symptoms in adults discontinuing opioid use. Lucemyra works by reducing norepinephrine release, a neurotransmitter linked to withdrawal symptoms. While it can lessen symptom severity, it does not completely prevent them and is approved for treatment durations of up to 14 days.
-
Leading companies advancing OWS therapies include Chiesi Farmaceutici S.p.A., BioXcel Therapeutics, Aphios Pharmaceutical, and others.
-
Notable pipeline candidates in development include CHF-6563, BXCL501, among others.
Opioid Withdrawal Syndrome Pipeline Analysis
The Opioid Withdrawal Syndrome pipeline insights report 2025, provides insights into:
-
Provides comprehensive insights into key companies developing therapies in the Opioid Withdrawal Syndrome Market.
-
Categorizes Opioid Withdrawal Syndrome therapeutic companies by development stage: early, mid, and late-stage.
-
Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.
-
Reviews emerging Opioid Withdrawal Syndrome drugs under development based on:
-
Stage of development
-
Opioid Withdrawal Syndrome Route of administration
-
Target receptor
-
Monotherapy vs. combination therapy
-
Opioid Withdrawal Syndrome Mechanism of action
-
Molecular type
-
-
Offers detailed analysis of:
-
Company-to-company and company-academia collaborations
-
Opioid Withdrawal Syndrome Licensing agreements
-
Funding and investment activities supporting future Opioid Withdrawal Syndrome market advancement.
-
Request for a sample report @ https://www.delveinsight.com/sample-request/obstructive-sleep-apnea-osa-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Opioid Withdrawal Syndrome Emerging Drugs
-
CHF-6563: Chiesi Farmaceutici S.p.A.
-
BXCL501: BioXcel Therapeutics
Opioid Withdrawal Syndrome Companies
More than four leading companies are actively developing treatments for Opioid Withdrawal Syndrome, with Chiesi Farmaceutici S.p.A. advancing a drug candidate to the most advanced stage to date—Phase II clinical trials.
DelveInsight’s report covers around 4+ products under different phases of Opioid Withdrawal Syndrome clinical trials like
-
Opioid Withdrawal Syndrome Late stage Therapies (Phase III)
-
Opioid Withdrawal Syndrome Mid-stage Therapies (Phase II)
-
Opioid Withdrawal Syndrome Early-stage Therapies (Phase I)
-
Opioid Withdrawal Syndrome Pre-clinical and Opioid Withdrawal Syndrome Discovery stage Therapies
-
Opioid Withdrawal Syndrome Discontinued & Inactive Therapies
Opioid Withdrawal Syndrome pipeline report provides the Opioid Withdrawal Syndrome therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
-
Intravenous
-
Subcutaneous
-
Oral
-
Intramuscular
Opioid Withdrawal Syndrome Products have been categorized under various Molecule types such as
-
Monoclonal antibody
-
Small molecule
-
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Opioid Withdrawal Syndrome Therapies and Key Opioid Withdrawal Syndrome Companies: Opioid Withdrawal Syndrome Clinical Trials and recent advancements
Opioid Withdrawal Syndrome Pipeline Therapeutic Assessment
• Opioid Withdrawal Syndrome Assessment by Product Type
• Opioid Withdrawal Syndrome By Stage
• Opioid Withdrawal Syndrome Assessment by Route of Administration
• Opioid Withdrawal Syndrome Assessment by Molecule Type
Download Opioid Withdrawal Syndrome Sample report to know in detail about the Opioid Withdrawal Syndrome treatment market @ Opioid Withdrawal Syndrome Therapeutic Assessment
Table of Content
1. Report Introduction
2. Executive Summary
3. Opioid Withdrawal Syndrome Current Treatment Patterns
4. Opioid Withdrawal Syndrome - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Opioid Withdrawal Syndrome Late-Stage Products (Phase-III)
7. Opioid Withdrawal Syndrome Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Opioid Withdrawal Syndrome Discontinued Products
13. Opioid Withdrawal Syndrome Product Profiles
14. Opioid Withdrawal Syndrome Key Companies
15. Opioid Withdrawal Syndrome Key Products
16. Dormant and Discontinued Products
17. Opioid Withdrawal Syndrome Unmet Needs
18. Opioid Withdrawal Syndrome Future Perspectives
19. Opioid Withdrawal Syndrome Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Opioid Withdrawal Syndrome Pipeline Reports Offerings
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
